Menu
Search
|

Menu

Close
X

Amarin Corporation PLC AMRN.OQ (NASDAQ Stock Exchange Global Market)

2.78 USD
-0.02 (-0.71%)
As of 7:34 PM IST
chart
Previous Close 2.80
Open 2.81
Volume 90,740
3m Avg Volume 446,500
Today’s High 2.81
Today’s Low 2.77
52 Week High 4.59
52 Week Low 2.67
Shares Outstanding (mil) 270.79
Market Capitalization (mil) 950.48
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
44
FY17
181
FY16
130
FY15
82
EPS (USD)
FY18
-0.084
FY17
-0.242
FY16
-0.411
FY15
-0.826
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
6.28
5.73
Price to Book (MRQ)
vs sector
--
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
--
16.84
LT Debt to Equity (MRQ)
vs sector
--
12.51
Return on Investment (TTM)
vs sector
-101.25
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Lars Ekman
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
John Thero
President, Chief Executive Officer, Assistant Secretary, Director, Since 2014
Salary: $500,000.00
Bonus: $243,750.00
Michael Kalb
Chief Financial Officer, Senior Vice President, Since 2016
Salary: --
Bonus: --
Stephen Ketchum
President - Research and Development, Senior Vice President, Chief Scientific Officer, Since 2016
Salary: $404,750.00
Bonus: $118,592.00
Joseph Kennedy
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary, Since 2012
Salary: $400,917.00
Bonus: $125,473.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Gemini House, Bartholomews Walk
DUBLIN     FK7 9JQ

Phone: +3531.6699020

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

SPONSORED STORIES